That would be a positive development....I do think that a deal will be announced after the end of PII meeting with FDA. My reasoning is that a BP probably wants to know how large and how long the phase III trial would be before agreeing to the final price on the deal. As you have mentioned though, there is a possibility the FDA could conditionally approve B-OM at the end of Phase II meeting since it is an unmet need (potentially fatal) and there is a significant amount of safety data for Brilacidin already. That would definitely have an impact on the share price....all IMHO.